T

Tarsier Pharma Ltd.

TARXDormant

Tarsier Pharma Ltd. · NYSE · Research source · F-1/A · 2026-07-16

Report source
Research source · F-1/A · 2026-07-16
SummaryBASIC RESEARCHReport source · F-1/A

IPO research

Tarsier Pharma’s preliminary IPO contemplates 5,555,555 ordinary shares at $8.00–$10.00 per share and a proposed NYSE listing under TARX.

Full source-backed summary

Tarsier Pharma is proposing an NYSE IPO of 5,555,555 ordinary shares at an estimated $8.00–$10.00 per share. The company is a loss-making, late-clinical-stage biopharmaceutical issuer whose lead candidate has not met its primary Phase 3 endpoint; substantial clinical, regulatory, financing and dilution risks remain.

Tarsier Pharma’s preliminary IPO contemplates 5,555,555 ordinary shares at $8.00–$10.00 per share and a proposed NYSE listing under TARX.

Ownership and votingAwaiting verified holder data— economic · — voting
Next disclosed checkpointEffectiveness of the registration statement, pricing and closing of the proposed IPO; dates are not yet supplied.F-1/A · 2026-07-16
Business and development direction

Tarsier Pharma Ltd.

Current business
Future development
DECISION DRIVERS

Key risks

Risk 1

The company expects continued substantial losses and estimates $65–$85 million may be required to execute its TRS01 commercialization plan.

Risk 2

No assurance is given that the NYSE listing will be approved or that an active trading market will develop.

Next checkEffectiveness of the registration statement, pricing and closing of the proposed IPO; dates are not yet supplied.
Latest filing2026-07-16
Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Offering qualitySome sourced inputs are available; a compatible set is needed for this view. Open filing ↗
BOOKRUNNERS / LEAD UNDERWRITERSUnderwriters named in the prospectus
PRELIMINARY
#InstitutionUnderwriting allocationRatioShares
1Konik Capital Partners, LLC, a division of T.R. Winston
Source and calculation

Names are explicitly identified in source underwriting tables or role clauses. Quantities require the named firm's own table row; missing allocations are not inferred.

Source · F-1/A ↗

IPO CAPITAL QUALITY

Shares offered Shares5,555,555
Basis and evidence

F-1/A · 2026-07-16

Tarsier Pharma’s preliminary IPO contemplates 5,555,555 ordinary shares at $8.00–$10.00 per share and a proposed NYSE listing under TARX.

Offering structure

Offering terms
MeasureReported valueUnit
Shares offered5,555,555Shares
Source and calculation

Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.

Shares offered

Prospectus offering table; stated base scenario and source conditions

SEC table 6 row 1; source 273677:293997; SHA256 2f9e8baa7413d271156aa359dff99e76f15d6ef7f00bfbf9b699cc5c2abaee7b ↗
Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Use of proceedsSource-linked structured inputs are not yet available. Open filing ↗

Dilution and valuation

IPO price—
Basic post-offer≈ 29.2918M
Equity value—

Reported figures remain on their stated basis. Exact compatible price and whole-issuer post-offer inputs are required for calculations.

Dilution and valuation
CalculationSharesValueReference
Post-offer shares — base/no option29,291,825—
Reported sourcePost-offer · BasesharesBasis and evidence 1 ↗
Post-offer shares — full option30,125,158—
Reported sourcePost-offer · Full optionsharesBasis and evidence 2 ↗
Shares offered5,555,555—
Reported sourcePost-offer · BasesharesBasis and evidence 3 ↗
Basis and evidence ↗
Basis and evidence 1

Prospectus share summary; Ordinary shares to be outstanding after this offering; 29,291,825 shares (or 30,125,158 shares if the underwriter exercises its over-allotment option in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value

Figures retain their stated source scenario and conditions.

Exact input · Post-offer shares — base/no option: 29,291,825

SEC table 6 row 2 columns 3; share summary; label column 1; source 273677:293997; SHA256 2f9e8baa7413d271156aa359dff99e76f15d6ef7f00bfbf9b699cc5c2abaee7b ↗

Basis and evidence 2

Prospectus share summary; Ordinary shares to be outstanding after this offering; 29,291,825 shares (or 30,125,158 shares if the underwriter exercises its over-allotment option in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value

Figures retain their stated source scenario and conditions.

SEC table 6 row 2 columns 3; share summary; label column 1; source 273677:293997; SHA256 2f9e8baa7413d271156aa359dff99e76f15d6ef7f00bfbf9b699cc5c2abaee7b ↗

Basis and evidence 3

Prospectus offering table; stated base scenario and source conditions

Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.

SEC table 6 row 1; source 273677:293997; SHA256 2f9e8baa7413d271156aa359dff99e76f15d6ef7f00bfbf9b699cc5c2abaee7b ↗

Share-count comparison

A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.

Source ↗
SCENARIO · NOT A FORECAST

IPO valuation scenario simulator

Source inputs required

Source facts remain available under their explicit security, scenario, period and precision; required compatible inputs are incomplete.

Source ↗
Implied equity value—Price × post-offer shares
Post-offer shares—Share count, not tradable float
Existing-holder ownership reduction—Assumes new shares only; secondary sales do not increase shares.
Source and calculation ↗
Security and offer price

Compatible source-bound inputs are not available; absence is not a non-disclosure finding.

Base post-offer shares

Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.

Equity value

Source facts remain available under their explicit security, scenario, period and precision; required compatible inputs are incomplete.

Share-count change

A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.

Alternative scenarios

Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.

Sensitivity

Source facts remain available under their explicit security, scenario, period and precision; required compatible inputs are incomplete.

Source and calculation

The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.

Sources and calculation notes

Read this report’s SEC filing ↗

Calculation inputs
ViewSource basis
Ownership across stagesSome sourced inputs are available; a compatible set is needed for this view. Open filing ↗
As of
2026-07-16
!Before the offering, Daphne Haim-Langford beneficially owns 29.8%; directors and executive officers as a group own 33.4%. Alkaloida Chemical Company owns 20.06%, Oriella 10.8% and AJ Tarsier Investment 8.13%. No different voting rights are disclosed.View source ↗
Relationship filters
Show
ownership / voting rights
share structure
Select for details · Tarsier Pharma Ltd.
Founder / personFund / entityPublic floatShare classEvery relationship is dated and linked to its supporting SEC filing. Percentages marked * are filing-based estimates.

Holdings and voting rights

Holder groups may overlap; these rows are not an additive ownership partition.

Holdings and voting rights
Holder / measureSharesOwnershipVoting rightsReference
Daphne Haim-Langford, Ph.D.Beneficial shares7,068,350——
Ordinary Shares Beneficially Owned; source column 3; stage header not connectedDisclosedEvidence
Zohar Milman, M.Sc.Beneficial shares570,630——
Ordinary Shares Beneficially Owned; source column 3; stage header not connectedDisclosedEvidence
Ron Neumann, M.D.Beneficial shares287,720——
Ordinary Shares Beneficially Owned; source column 3; stage header not connectedDisclosedEvidence
Susan Benton, MBABeneficial shares127,020——
Ordinary Shares Beneficially Owned; source column 3; stage header not connectedDisclosedEvidence
Sascha Bucher, MBABeneficial shares127,020——
Ordinary Shares Beneficially Owned; source column 3; stage header not connectedDisclosedEvidence
All directors and executive officers as a group (8 persons)Beneficial shares8,751,370——
Ordinary Shares Beneficially Owned; source column 3; stage header not connectedDisclosedEvidence
AJ Tarsier Investment LLCBeneficial shares1,929,000——
Ordinary Shares Beneficially Owned; source column 3; stage header not connectedDisclosedEvidence
Oriella Ltd.Beneficial shares2,563,700——
Ordinary Shares Beneficially Owned; source column 3; stage header not connectedDisclosedEvidence
Alkaloida Chemical Company zrt.Beneficial shares4,762,840——
Ordinary Shares Beneficially Owned; source column 3; stage header not connectedDisclosedEvidence
Daphne Haim-Langford, Ph.D.Beneficial ownership—29.8%Beneficial—
Percent of Ordinary Shares Beneficially Owned Before OfferingDisclosedEvidence
Daphne Haim-Langford, Ph.D.Beneficial ownership—23.5%Beneficial—
Percent of Ordinary Shares Beneficially Owned After OfferingDisclosedEvidence
Zohar Milman, M.Sc.Beneficial ownership—2.4%Beneficial—
Percent of Ordinary Shares Beneficially Owned Before OfferingDisclosedEvidence
Zohar Milman, M.Sc.Beneficial ownership—1.9%Beneficial—
Percent of Ordinary Shares Beneficially Owned After OfferingDisclosedEvidence
Ron Neumann, M.D.Beneficial ownership—1.2%Beneficial—
Percent of Ordinary Shares Beneficially Owned Before OfferingDisclosedEvidence
Ron Neumann, M.D.Beneficial ownership—0.9%Beneficial—
Percent of Ordinary Shares Beneficially Owned After OfferingDisclosedEvidence
All directors and executive officers as a group (8 persons)Beneficial ownership—33.4%Beneficial—
Percent of Ordinary Shares Beneficially Owned Before OfferingDisclosedEvidence
All directors and executive officers as a group (8 persons)Beneficial ownership—26.3%Beneficial—
Percent of Ordinary Shares Beneficially Owned After OfferingDisclosedEvidence
AJ Tarsier Investment LLCBeneficial ownership—8.13%Beneficial—
Percent of Ordinary Shares Beneficially Owned Before OfferingDisclosedEvidence
AJ Tarsier Investment LLCBeneficial ownership—6.4%Beneficial—
Percent of Ordinary Shares Beneficially Owned After OfferingDisclosedEvidence
Oriella Ltd.Beneficial ownership—10.8%Beneficial—
Percent of Ordinary Shares Beneficially Owned Before OfferingDisclosedEvidence
Oriella Ltd.Beneficial ownership—8.5%Beneficial—
Percent of Ordinary Shares Beneficially Owned After OfferingDisclosedEvidence
Alkaloida Chemical Company zrt.Beneficial ownership—20.06%Beneficial—
Percent of Ordinary Shares Beneficially Owned Before OfferingDisclosedEvidence
Alkaloida Chemical Company zrt.Beneficial ownership—15.8%Beneficial—
Percent of Ordinary Shares Beneficially Owned After OfferingDisclosedEvidence
Ordinary Shareper-share voting rights——1 vote per shareVotes per share
Literal source per-share voting entitlement; Ordinary Share; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retainedDisclosedEvidence
Source and calculation ↗
Daphne Haim-Langford, Ph.D. · Daphne Haim-Langford, Ph.D. — Beneficial shares · 7,068,350

Exact source ownership column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; holders may overlap; not an additive partition

Raw source column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; source holder: Daphne Haim-Langford, Ph.D.

0001213900-26-078792 · SEC table 20 row 3 columns 3; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:3 ↗

Zohar Milman, M.Sc. · Zohar Milman, M.Sc. — Beneficial shares · 570,630

Exact source ownership column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; holders may overlap; not an additive partition

Raw source column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; source holder: Zohar Milman, M.Sc.(1)

0001213900-26-078792 · SEC table 20 row 5 columns 3; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:3 ↗

Ron Neumann, M.D. · Ron Neumann, M.D. — Beneficial shares · 287,720

Exact source ownership column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; holders may overlap; not an additive partition

Raw source column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; source holder: Ron Neumann, M.D.(1)

0001213900-26-078792 · SEC table 20 row 6 columns 3; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:3 ↗

Susan Benton, MBA · Susan Benton, MBA — Beneficial shares · 127,020

Exact source ownership column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; holders may overlap; not an additive partition

Raw source column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; source holder: Susan Benton, MBA(1)

0001213900-26-078792 · SEC table 20 row 8 columns 3; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:3 ↗

Sascha Bucher, MBA · Sascha Bucher, MBA — Beneficial shares · 127,020

Exact source ownership column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; holders may overlap; not an additive partition

Raw source column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; source holder: Sascha Bucher, MBA

0001213900-26-078792 · SEC table 20 row 9 columns 3; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:3 ↗

All directors and executive officers as a group (8 persons) · All directors and executive officers as a group (8 persons) — Beneficial shares · 8,751,370

Exact source ownership column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; holders may overlap; not an additive partition

Raw source column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; source holder: All directors and executive officers as a group (8 persons)

0001213900-26-078792 · SEC table 20 row 11 columns 3; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:3 ↗

AJ Tarsier Investment LLC · AJ Tarsier Investment LLC — Beneficial shares · 1,929,000

Exact source ownership column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; holders may overlap; not an additive partition

Raw source column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; source holder: AJ Tarsier Investment LLC(2)

0001213900-26-078792 · SEC table 20 row 13 columns 3; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:3 ↗

Oriella Ltd. · Oriella Ltd. — Beneficial shares · 2,563,700

Exact source ownership column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; holders may overlap; not an additive partition

Raw source column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; source holder: Oriella Ltd.(3)

0001213900-26-078792 · SEC table 20 row 14 columns 3; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:3 ↗

Alkaloida Chemical Company zrt. · Alkaloida Chemical Company zrt. — Beneficial shares · 4,762,840

Exact source ownership column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; holders may overlap; not an additive partition

Raw source column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; source holder: Alkaloida Chemical Company zrt.(4)

0001213900-26-078792 · SEC table 20 row 15 columns 3; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:3 ↗

Daphne Haim-Langford, Ph.D. · Daphne Haim-Langford, Ph.D. — Beneficial ownership · 29.8%

Exact source ownership column: Percent of Ordinary Shares Beneficially Owned Before Offering; holders may overlap; not an additive partition

Raw source column: Percent of Ordinary Shares Beneficially Owned Before Offering; source holder: Daphne Haim-Langford, Ph.D.

0001213900-26-078792 · SEC table 20 row 3 columns 5,6; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:5 ↗

Daphne Haim-Langford, Ph.D. · Daphne Haim-Langford, Ph.D. — Beneficial ownership · 23.5%

Exact source ownership column: Percent of Ordinary Shares Beneficially Owned After Offering; holders may overlap; not an additive partition

Raw source column: Percent of Ordinary Shares Beneficially Owned After Offering; source holder: Daphne Haim-Langford, Ph.D.

0001213900-26-078792 · SEC table 20 row 3 columns 8,9; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:7 ↗

Zohar Milman, M.Sc. · Zohar Milman, M.Sc. — Beneficial ownership · 2.4%

Exact source ownership column: Percent of Ordinary Shares Beneficially Owned Before Offering; holders may overlap; not an additive partition

Raw source column: Percent of Ordinary Shares Beneficially Owned Before Offering; source holder: Zohar Milman, M.Sc.(1)

0001213900-26-078792 · SEC table 20 row 5 columns 5,6; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:5 ↗

Zohar Milman, M.Sc. · Zohar Milman, M.Sc. — Beneficial ownership · 1.9%

Exact source ownership column: Percent of Ordinary Shares Beneficially Owned After Offering; holders may overlap; not an additive partition

Raw source column: Percent of Ordinary Shares Beneficially Owned After Offering; source holder: Zohar Milman, M.Sc.(1)

0001213900-26-078792 · SEC table 20 row 5 columns 8,9; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:7 ↗

Ron Neumann, M.D. · Ron Neumann, M.D. — Beneficial ownership · 1.2%

Exact source ownership column: Percent of Ordinary Shares Beneficially Owned Before Offering; holders may overlap; not an additive partition

Raw source column: Percent of Ordinary Shares Beneficially Owned Before Offering; source holder: Ron Neumann, M.D.(1)

0001213900-26-078792 · SEC table 20 row 6 columns 5,6; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:5 ↗

Ron Neumann, M.D. · Ron Neumann, M.D. — Beneficial ownership · 0.9%

Exact source ownership column: Percent of Ordinary Shares Beneficially Owned After Offering; holders may overlap; not an additive partition

Raw source column: Percent of Ordinary Shares Beneficially Owned After Offering; source holder: Ron Neumann, M.D.(1)

0001213900-26-078792 · SEC table 20 row 6 columns 8,9; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:7 ↗

All directors and executive officers as a group (8 persons) · All directors and executive officers as a group (8 persons) — Beneficial ownership · 33.4%

Exact source ownership column: Percent of Ordinary Shares Beneficially Owned Before Offering; holders may overlap; not an additive partition

Raw source column: Percent of Ordinary Shares Beneficially Owned Before Offering; source holder: All directors and executive officers as a group (8 persons)

0001213900-26-078792 · SEC table 20 row 11 columns 5,6; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:5 ↗

All directors and executive officers as a group (8 persons) · All directors and executive officers as a group (8 persons) — Beneficial ownership · 26.3%

Exact source ownership column: Percent of Ordinary Shares Beneficially Owned After Offering; holders may overlap; not an additive partition

Raw source column: Percent of Ordinary Shares Beneficially Owned After Offering; source holder: All directors and executive officers as a group (8 persons)

0001213900-26-078792 · SEC table 20 row 11 columns 8,9; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:7 ↗

AJ Tarsier Investment LLC · AJ Tarsier Investment LLC — Beneficial ownership · 8.13%

Exact source ownership column: Percent of Ordinary Shares Beneficially Owned Before Offering; holders may overlap; not an additive partition

Raw source column: Percent of Ordinary Shares Beneficially Owned Before Offering; source holder: AJ Tarsier Investment LLC(2)

0001213900-26-078792 · SEC table 20 row 13 columns 5,6; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:5 ↗

AJ Tarsier Investment LLC · AJ Tarsier Investment LLC — Beneficial ownership · 6.4%

Exact source ownership column: Percent of Ordinary Shares Beneficially Owned After Offering; holders may overlap; not an additive partition

Raw source column: Percent of Ordinary Shares Beneficially Owned After Offering; source holder: AJ Tarsier Investment LLC(2)

0001213900-26-078792 · SEC table 20 row 13 columns 8,9; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:7 ↗

Oriella Ltd. · Oriella Ltd. — Beneficial ownership · 10.8%

Exact source ownership column: Percent of Ordinary Shares Beneficially Owned Before Offering; holders may overlap; not an additive partition

Raw source column: Percent of Ordinary Shares Beneficially Owned Before Offering; source holder: Oriella Ltd.(3)

0001213900-26-078792 · SEC table 20 row 14 columns 5,6; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:5 ↗

Oriella Ltd. · Oriella Ltd. — Beneficial ownership · 8.5%

Exact source ownership column: Percent of Ordinary Shares Beneficially Owned After Offering; holders may overlap; not an additive partition

Raw source column: Percent of Ordinary Shares Beneficially Owned After Offering; source holder: Oriella Ltd.(3)

0001213900-26-078792 · SEC table 20 row 14 columns 8,9; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:7 ↗

Alkaloida Chemical Company zrt. · Alkaloida Chemical Company zrt. — Beneficial ownership · 20.06%

Exact source ownership column: Percent of Ordinary Shares Beneficially Owned Before Offering; holders may overlap; not an additive partition

Raw source column: Percent of Ordinary Shares Beneficially Owned Before Offering; source holder: Alkaloida Chemical Company zrt.(4)

0001213900-26-078792 · SEC table 20 row 15 columns 5,6; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:5 ↗

Alkaloida Chemical Company zrt. · Alkaloida Chemical Company zrt. — Beneficial ownership · 15.8%

Exact source ownership column: Percent of Ordinary Shares Beneficially Owned After Offering; holders may overlap; not an additive partition

Raw source column: Percent of Ordinary Shares Beneficially Owned After Offering; source holder: Alkaloida Chemical Company zrt.(4)

0001213900-26-078792 · SEC table 20 row 15 columns 8,9; source 1851348:1931088; SHA256 9a9a233a4d28f536c5c0cd00b1e4899a3153fe9d752d11a96df8955327deb6f6; ownership header cells 1:7 ↗

Ordinary Share · Ordinary Share — per-share voting rights · 1 vote per share

Literal source per-share voting entitlement; Ordinary Share; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retained

• equal right to attend and to vote at all of our general meetings, whether regular or special, with each Ordinary Share entitling the holder thereof, which attend the meeting and participate at the voting, either in person or by a proxy or by a written ballot, to one vote; Source context: Upon the closing of this offering, our authorized share capital will consist of 100,000,000 ordinary shares, par value NIS 0.001 per share, of which, effective immediately prior to the closing of this offering, 29,291,825 shares will be issued and outstanding (assuming that the underwriter does not exercise its option to purchase additional ordinary shares).

0001213900-26-078792 · SEC ownership excerpt; source 1978252:1979109; SHA256 6d0bf44c1e8ce1763253c40f00bf172956ca4f1ccd4a202069a3229aa54b8140; context source 1959324:1960423; SHA256 c8928140e20e2dd265dca659b635c4aa50ad8fb0d72fad083b2e59a16ebe094b ↗

Economic ownership

A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.

Share supply

Source lock-up conditions

Literal day restriction; after closing of this offering; full conditions and exceptions remain in the source paragraph

Source lock-up conditions
MeasureReported value
We and our officers and directors, and the holders of 5.0% or more of the outstanding ordinary shares prior to this offering,After closing of this offering · Source conditions apply180 days
Source and calculation
We and our officers and directors, and the holders of 5.0% or more of the outstanding ordinary shares prior to this offering,

We and our officers and directors, and the holders of 5.0% or more of the outstanding ordinary shares prior to this offering, have agreed, subject to limited exceptions, for a period of 180 days after the closing of this offering, not to offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of, directly or indirectly any ordinary shares or ordinary shares or any securities convertible into or exchangeable for our ordinary shares or the ordinary shares either owned as of the date of the underwriting agreement or thereafter acquired without the prior written consent of the underwriter. The underwriter may, in its sole discretion and at any time or from time to time before the termination of the lock-up period, without notice, release all or any portion of the securities subject to lock-up agreements.

SEC lock-up paragraph; source 2154099:2155385; SHA256 34dd61b389efcc807687dff4916c6cc9c5a8946fdb42119a8c657db1bff5d244 ↗

Source lock-up conditions

Literal day restriction; anchor not separately resolved; full conditions and exceptions remain in the source paragraph

Source lock-up conditions
MeasureReported value
the warrants180 days
Source and calculation
the warrants

issued in this offering. The warrants are deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1)(A) of FINRA. The underwriter (or its permitted assignees under Rule 5110(e)(2) of FINRA) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will it engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a 180 day period from the commencement of sales of the ordinary shares in this offering. The warrants will expire five years from the commencement of sales of ordinary shares in this offering. The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary cash dividend or our recapitalization, reorganization, merger, or consolidation. We have agreed to a one time demand registration of the ordinary shares underlying the warrants for a period of five years from the commencement of sales of this offering. The warrants also provide for unlimited “piggyback” registration rights at our expense with respect to the underlying ordinary shares during the five year period from the commencement of sales of this offering. The underwriter’s warrants and the ordinary shares underlying the underwriter’s warrants are being registered on the registration statement of which this prospectus forms a part.

SEC lock-up paragraph; source 2164779:2166846; SHA256 74e0317177509bf0cabfad278f7eab276d06b958fdebf6c612bc283ea4f13646 ↗

Conditional lock-up timeline

Conditional lock-up timeline

Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.

closing of this offering

  1. We and our officers and directors, and the holders of 5.0% or more of the outstanding ordinary shares prior to this offering,We and our officers and directors, and the holders of 5.0% or more of the outstanding ordinary shares prior to this offering, have agreed, subject to limited exceptions, for a period of 180 days after the closing of this offering, not to offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of, directly or indirectly any ordinary shares or ordinary shares or any securities convertible into or exchangeable for our ordinary shares or the ordinary shares either owned as of the date of the underwriting agreement or thereafter acquired without the prior written consent of the underwriter. The underwriter may, in its sole discretion and at any time or from time to time before the termination of the lock-up period, without notice, release all or any portion of the securities subject to lock-up agreements.
Holder / event
Holder / eventTerm / dateConditions
We and our officers and directors, and the holders of 5.0% or more of the outstanding ordinary shares prior to this offering,180 daysWe and our officers and directors, and the holders of 5.0% or more of the outstanding ordinary shares prior to this offering, have agreed, subject to limited exceptions, for a period of 180 days after the closing of this offering, not to offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of, directly or indirectly any ordinary shares or ordinary shares or any securities convertible into or exchangeable for our ordinary shares or the ordinary shares either owned as of the date of the underwriting agreement or thereafter acquired without the prior written consent of the underwriter. The underwriter may, in its sole discretion and at any time or from time to time before the termination of the lock-up period, without notice, release all or any portion of the securities subject to lock-up agreements.

Milestones and unconfirmed releases

Holder / event
Holder / eventTerm / dateConditions
the warrants180 daysissued in this offering. The warrants are deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1)(A) of FINRA. The underwriter (or its permitted assignees under Rule 5110(e)(2) of FINRA) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will it engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a 180 day period from the commencement of sales of the ordinary shares in this offering. The warrants will expire five years from the commencement of sales of ordinary shares in this offering. The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary cash dividend or our recapitalization, reorganization, merger, or consolidation. We have agreed to a one time demand registration of the ordinary shares underlying the warrants for a period of five years from the commencement of sales of this offering. The warrants also provide for unlimited “piggyback” registration rights at our expense with respect to the underlying ordinary shares during the five year period from the commencement of sales of this offering. The underwriter’s warrants and the ordinary shares underlying the underwriter’s warrants are being registered on the registration statement of which this prospectus forms a part.
Basis and evidence
We and our officers and directors, and the holders of 5.0% or more of the outstanding ordinary shares prior to this offering,

We and our officers and directors, and the holders of 5.0% or more of the outstanding ordinary shares prior to this offering, have agreed, subject to limited exceptions, for a period of 180 days after the closing of this offering, not to offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of, directly or indirectly any ordinary shares or ordinary shares or any securities convertible into or exchangeable for our ordinary shares or the ordinary shares either owned as of the date of the underwriting agreement or thereafter acquired without the prior written consent of the underwriter. The underwriter may, in its sole discretion and at any time or from time to time before the termination of the lock-up period, without notice, release all or any portion of the securities subject to lock-up agreements.

SEC lock-up paragraph; source 2154099:2155385; SHA256 34dd61b389efcc807687dff4916c6cc9c5a8946fdb42119a8c657db1bff5d244 ↗
the warrants

issued in this offering. The warrants are deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1)(A) of FINRA. The underwriter (or its permitted assignees under Rule 5110(e)(2) of FINRA) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will it engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a 180 day period from the commencement of sales of the ordinary shares in this offering. The warrants will expire five years from the commencement of sales of ordinary shares in this offering. The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary cash dividend or our recapitalization, reorganization, merger, or consolidation. We have agreed to a one time demand registration of the ordinary shares underlying the warrants for a period of five years from the commencement of sales of this offering. The warrants also provide for unlimited “piggyback” registration rights at our expense with respect to the underlying ordinary shares during the five year period from the commencement of sales of this offering. The underwriter’s warrants and the ordinary shares underlying the underwriter’s warrants are being registered on the registration statement of which this prospectus forms a part.

SEC lock-up paragraph; source 2164779:2166846; SHA256 74e0317177509bf0cabfad278f7eab276d06b958fdebf6c612bc283ea4f13646 ↗

Financial quality

Bars compare absolute amounts within each measure. Each measure has its own scale.

Net income / (loss)

USD · Annual values as reported
FY2024USD 2,456,000
FY2025USD 5,070,000

Operating cash flow

USD · Annual values as reported
FY2024(USD 1,913,000)
FY2025(USD 1,318,000)
Financial quality
CalculationFY2024FY2025
Net income / (loss)USD 2,456,000USD 5,070,000
Operating cash flow(USD 1,913,000)(USD 1,318,000)
Financial quality
CalculationReported valueReference
Cash and cash equivalents2025-12-31USD 1,999,000December 31, 2025; issuer; USD; as of 2025-12-31
Cash and cash equivalents2024-12-31USD 1,218,000December 31, 2024; issuer; USD; as of 2024-12-31
Current assets2025-12-31USD 2,015,000December 31, 2025; issuer; USD; as of 2025-12-31
Current assets2024-12-31USD 1,266,000December 31, 2024; issuer; USD; as of 2024-12-31
Total assets2025-12-31USD 2,325,000December 31, 2025; issuer; USD; as of 2025-12-31
Total assets2024-12-31USD 1,287,000December 31, 2024; issuer; USD; as of 2024-12-31
Current liabilities2025-12-31USD 812,000December 31, 2025; issuer; USD; as of 2025-12-31
Current liabilities2024-12-31USD 561,000December 31, 2024; issuer; USD; as of 2024-12-31
Total equity / (deficit)2025-12-31(USD 4,991,000)December 31, 2025; issuer; USD; as of 2025-12-31
Total equity / (deficit)2024-12-31(USD 2,765,000)December 31, 2024; issuer; USD; as of 2024-12-31
General and administrative expensesFY2025USD 544,000FY2025; issuer; USD; year ended 2025-12-31
General and administrative expensesFY2024USD 364,000FY2024; issuer; USD; year ended 2024-12-31
Basis and evidence
Cash and cash equivalents
December 31, 2025; issuer; USD; as of 2025-12-31
Cash and cash equivalents
December 31, 2024; issuer; USD; as of 2024-12-31
Total current assets
December 31, 2025; issuer; USD; as of 2025-12-31
Total current assets
December 31, 2024; issuer; USD; as of 2024-12-31
Total assets
December 31, 2025; issuer; USD; as of 2025-12-31
Total assets
December 31, 2024; issuer; USD; as of 2024-12-31
Total current liabilities
December 31, 2025; issuer; USD; as of 2025-12-31
Total current liabilities
December 31, 2024; issuer; USD; as of 2024-12-31
Total shareholders’ deficit
December 31, 2025; issuer; USD; as of 2025-12-31
Total shareholders’ deficit
December 31, 2024; issuer; USD; as of 2024-12-31
General and administrative expenses
FY2025; issuer; USD; year ended 2025-12-31
General and administrative expenses
FY2024; issuer; USD; year ended 2024-12-31
Net loss for the year
FY2025; issuer; USD; year ended 2025-12-31
Net loss for the year
FY2024; issuer; USD; year ended 2024-12-31
Net cash used in operating activities
FY2025; issuer; USD; year ended 2025-12-31
Net cash used in operating activities
FY2024; issuer; USD; year ended 2024-12-31
Financial quality and runway
Financial review

Financial quality and runway

Audited U.S. GAAP financial statements cover 2024 and 2025. The company reported 2025 net loss of $5.070 million, accumulated deficit of $26.929 million and cash of $1.999 million as of December 31, 2025. The auditor highlighted substantial doubt about going concern.

Cash and cash equivalentsUSD 1,999,000
Cash and cash equivalentsUSD 1,218,000
Total current assetsUSD 2,015,000
EvidenceFinancial review 1

Net loss increased from $2.456 million in 2024 to $5.070 million in 2025.

EvidenceFinancial review 2

The auditor stated that losses, negative operating cash flows and accumulated deficit raise substantial doubt about going concern.

Source · Report of Independent Registered Public Accounting FirmOpen F-1/A ↗
LATEST COMPARISON

Baseline filing — comparison pending

No source-comparable material changes identified in this report.

Open F-1/A ↗

No source-comparable material changes identified in this report.

IPO177 explains the investment effect; the SEC source remains the authoritative record. Page-level locators are shown only when extracted and verified.

Loading filing history…

Risk 1

The company expects continued substantial losses and estimates $65–$85 million may be required to execute its TRS01 commercialization plan.

Risk 2

No assurance is given that the NYSE listing will be approved or that an active trading market will develop.

DocumentF-1/A0001213900-26-078792
Filed2026-07-16SEC EDGAR
Research updated2026-09-13Analysed
Source-bound table inputs42SEC EDGAR
Open filing ↗